Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 20/20 | 1.00 |
| ▸ | JAK2 | O60674 | 1/20 | 1.00 |
| ▸ | LCK | P06239 | 1/20 | 1.00 |
| ▸ | YES1 | P07947 | 1/20 | 1.00 |
| ▸ | LYN | P07948 | 1/20 | 1.00 |
| ▸ | FGR | P09769 | 1/20 | 1.00 |
| ▸ | SRC | P12931 | 1/20 | 1.00 |
| ▸ | PRKCA | P17252 | 1/20 | 1.00 |
| ▸ | FLT3 | P36888 | 1/20 | 1.00 |
| ▸ | ZAP70 | P43403 | 1/20 | 1.00 |
| ▸ | MAP3K9 | P80192 | 1/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 1/20 | 1.00 |
| ▸ | PAK5 | Q9P286 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1352147 | 1.00 | SYK (1.00) | SYKJAK2LCKYES1LYN | |
| SCHEMBL14977351 | 1.00 | SYK (1.00) | SYKJAK2LCKYES1LYN | |
| SCHEMBL13624896 | 1.00 | SYK (1.00) | SYKJAK2LCKYES1LYN | |
| SCHEMBL1353814 | 1.00 | SYK (1.00) | SYKJAK2LCKYES1LYN | |
| SCHEMBL900582 | 1.00 | SYK (1.00) | SYKJAK2LCKYES1LYN | |
| Hydrochloric Acid SCHEMBL29392320 | 0.99 | SYK (0.98) | SYKJAK2LCKYES1LYN | |
| Hydrochloric Acid SCHEMBL900878 | 0.99 | SYK (0.98) | SYKJAK2LCKYES1LYN | |
| SCHEMBL1353568 | 0.98 | SYK (1.00) | SYKJAK2LCKYES1LYN | |
| SCHEMBL1353566 | 0.98 | SYK (1.00) | SYKJAK2LCKYES1LYN | |
| SCHEMBL1353462 | 0.98 | SYK (1.00) | SYKJAK2LCKYES1LYN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1377 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260097056-A1 | SYK ACTIVATORS AND INHIBITORS IN NEURODEGENERATIVE DISEASES | UNIV VIRGINIA PATENT FOUNDATION (US) | 2026-04-09 | — | — | US | claimed |
| US-12594421-B2 | Compositions and methods for increasing cancer cell sensitivity to alternating electric fields | NOVOCURE GMBH (CH) | 2026-04-07 | — | — | US | claimed |
| WO-2025151443-A1 | ENDOXIFEN FOR TREATMENT OF RARE CANCERS | ATOSSA THERAPEUTICS, INC. (US) | 2025-07-17 | — | — | WO | claimed |
| US-20250186432-A1 | SPLEEN TYROSINE KINASE INHIBITOR, COMPOSITION, AND METHODS OF USE | PURDUE RESEARCH FOUNDATION | 2025-06-12 | — | — | US | claimed |
| WO-2025052354-A1 | SYK INHIBITORS FOR USE IN THE TREATMENT OF IMMUNE CHECKPOINT INHIBITION INDUCED ADVERSE EVENTS | ALBERT-LUDWIGS-UNIVERSITÄT FREIBURG (DE) | 2025-03-13 | — | — | WO | claimed |
| EP-4520333-A1 | SYK INHIBITORS FOR USE IN THE TREATMENT OF IMMUNE CHECKPOINT INHIBITION INDUCED ADVERSE EVENTS | Albert-Ludwigs-Universität Freiburg (DE) | 2025-03-12 | — | — | EP | claimed |
| US-20250025461-A1 | TREATMENT OF SEVERE AND UNCOMPLICATED MALARIA | NUREX S.R.L. (IT) | 2025-01-23 | — | — | US | claimed |
| EP-4493188-A2 | SPLEEN TYROSINE KINASE INHIBITOR, COMPOSITION, AND METHODS OF USE | Purdue Research Foundation (US) | 2025-01-22 | — | — | EP | claimed |
| CN-119300822-A | Spleen tyrosine kinase inhibitors, compositions, and methods of use | 普渡研究基金会 | 2025-01-10 | — | — | CN | claimed |
| US-20240398801-A1 | TREATMENT OF LEUKEMIA BASED ON LEUKEMIA HIERARCHY IN A PATIENT | UNIVERSITY HEALTH NETWORK (CA) | 2024-12-05 | — | — | US | claimed |
| CN-115429883-A | Antitumor pharmaceutical composition for combination therapy | 首药控股(北京)股份有限公司 | 2022-12-06 | — | — | CN | claimed |
| US-20220218659-A1 | PI3K/LYN-ACLY Signaling Inhibition | INSTITUTE FOR CANCER RESEARCH D/B/A THE RESEARCH INSTITUTE OF FOX CHASE CANCER CENTER | 2022-07-14 | — | — | US | claimed |
| US-20220096818-A1 | Compositions And Methods For Increasing Cancer Cell Sensitivity To Alternating Electric Fields | BIOPHARMA CREDIT PLC (GB) | 2022-03-31 | — | — | US | claimed |
| WO-2022035723-A1 | COMPOSITIONS, PANELS, AND METHODS FOR CHARACTERIZING CHRONIC LYMPHOCYTIC LEUKEMIA | THE BROAD INSTITUTE, INC. (US) | 2022-02-17 | — | — | WO | claimed |
| WO-2022029628-A1 | COMPOSITIONS AND METHODS FOR INCREASING CANCER CELL SENSITIVITY TO ALTERNATING ELECTRIC FIELDS | NOVOCURE GMBH (CH) | 2022-02-10 | — | — | WO | claimed |
| EP-2323993-B1 | 2,6-DIAMINO- PYRIMIDIN- 5-YL-CARBOXAMIDES AS SYK OR JAK KINASES INHIBITORS | PORTOLA PHARM INC (US) | 2015-06-03 | — | — | EP | claimed |
| US-20130252917-A1 | COMBINATION THERAPY OF 4-(3-(2H-1,2,3-TRIAZO-2-YL)PHENYLAMINO)-2-((1R,2S)-2-AMINOCYCLOHEXYLAMINO)PYRIMIDINE-5-CARBOXAMIDE AND FLUDARABINE | PORTOLA PHARMACEUTICALS, INC. (US) | 2013-09-26 | — | — | US | claimed |
| US-20130244963-A1 | COMBINATION THERAPY WITH 4-(3-(2H-1,2,3-TRIAZOL-2-YL)PHENYLAMINO)-2-((1R,2S)-2-AMINOCYCLOHEXYLAMINO)PYRIMIDINE-5-CARBOXAMIDE | PORTOLA PHARMACEUTICALS, INC. (US) | 2013-09-19 | — | — | US | claimed |
| WO-2012044936-A1 | COMBINATION THERAPY WITH 4-(3-(2H-1,2,3-TRIAZOL-2-YL)PHENYLAMINO)-2-((1R,2S)-2-AMINOCYCLOHEXYLAMINO)PYRIMIDINE-5-CARBOXAMIDE | PORTOLA PHARMACEUTICALS, INC. (US) | 2012-04-05 | — | — | WO | claimed |
| US-8063058-B2 | Inhibitors of syk and JAK protein kinases | PORTOLA PHARMACEUTICALS, INC. (US) | 2011-11-22 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250186432-A1 | SPLEEN TYROSINE KINASE INHIBITOR, COMPOSITION, AND METHODS OF USE | SYK, BTK, G6PD | SYK 1/4885JAK2 27/4885LCK 4/4885 |
| US-20130252917-A1 | COMBINATION THERAPY OF 4-(3-(2H-1,2,3-TRIAZO-2-YL)PHENYLAMINO)-2-((1R,2S)-2-AMINOCYCLOHEXYLAMINO)PYRIMIDINE-5-CARBOXAMIDE AND FLUDARABINE | BCL9, BCL9L, MCL1 | SYK 101/4885JAK2 137/4885LCK 848/4885 |
| US-20130244963-A1 | COMBINATION THERAPY WITH 4-(3-(2H-1,2,3-TRIAZOL-2-YL)PHENYLAMINO)-2-((1R,2S)-2-AMINOCYCLOHEXYLAMINO)PYRIMIDINE-5-CARBOXAMIDE | SYK, BCL9L, BCL9 | SYK 1/4885JAK2 11/4885LCK 26/4885 |
| US-20260097056-A1 | SYK ACTIVATORS AND INHIBITORS IN NEURODEGENERATIVE DISEASES | SYK, BTK, FYN | SYK 1/4885JAK2 464/4885LCK 13/4885 |
| US-12594421-B2 | Compositions and methods for increasing cancer cell sensitivity to alternating electric fields | PTK2, GSK3B, MTOR | SYK 478/4885JAK2 378/4885LCK 189/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.